<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="114392">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01996267</url>
  </required_header>
  <id_info>
    <org_study_id>M13TRT</org_study_id>
    <nct_id>NCT01996267</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer, TRAIN-2</brief_title>
  <acronym>TRAIN-2</acronym>
  <official_title>Optimizing Neoadjuvant Systemic Treatment for HER2 Positive Breast Cancer - the TRAIN-2 Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Netherlands Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Borstkanker Onderzoek Groep</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Netherlands Cancer Institute</source>
  <oversight_info>
    <authority>Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study compares two schedules of upfront chemotherapy in HER positive breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Upfront trastuzumab treatment is beneficial to patients with HER2 positive breast cancer.
      The potential synergistic cardiotoxicity of trastuzumab and anthracyclines has led to the
      development of non-anthracycline containing regimens, which have shown high pathologic
      complete response rates. Anthracyclines remain very active in HER2 positive breast cancer,
      however, and increasing evidence now supports safe combination of trastuzumab and
      epirubicin. Therefore, the addition of epirubicin to a non-anthracycline containing regimen
      may further improve outcome for patients with HER2 positive breast cancer.

      Several reports confirmed benefit of dual HER2 blockade by adding pertuzumab to a
      trastuzumab containing neoadjuvant regimen. The results of the combined treatment in the
      Neosphere study, however, are similar to what we found in a phase II trial using a weekly
      paclitaxel, trastuzumab, carboplatin combination with pCR rates of approximately 44%. Adding
      pertuzumab to this regimen is likely to also increase the high pCR rate and to add
      substantial benefit to patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of patients with pathological complete response</measure>
    <time_frame>at week 30</time_frame>
    <safety_issue>No</safety_issue>
    <description>To compare the efficacy of six cycles neoadjuvant PTC plus pertuzumab preceded by either three cycles of FEC-T plus pertuzumab or three cycles of PTC plus pertuzumab in HER2 positive breast cancer</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with grade &gt;2 adverse events as a measure of safety and tolerability</measure>
    <time_frame>up to week 35</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>to describe the safety of the various regimens toxicity is compared between the two arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>identify prognostic and predictive biomarkers for pCR</measure>
    <time_frame>within one year after end of treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>To identify prognostic and predictive biomarkers for pCR after neoadjuvant treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">437</enrollment>
  <condition>Breast Cancer</condition>
  <condition>HER2 Positive</condition>
  <arm_group>
    <arm_group_label>FEC-T +Pertuzumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fluorouracil; 500 mg/m2; day 1 Epirubicine; 90 mg/m2; day 1 Cyclophosphamide; 500 mg/m2; day 1 Trastuzumab; 6 mg/kg (loading dose 8 mg/kg) Pertuzumab; 420 mg (loading dose 840 mg); day 1 Cycle is repeated every 21 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PTC+Pertuzumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Paclitaxel; 80 mg/m2; day 1,8 Trastuzumab; 6 mg/kg (loading dose 8 mg/kg); day 1 Carboplatin; AUC=6; day 1 Pertuzumab; 420 mg (loading dose 840 mg); day 1 Cycle repeated every 21 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PTC+Pertuzumab</intervention_name>
    <arm_group_label>PTC+Pertuzumab</arm_group_label>
    <other_name>Paclitaxel; 80 mg/m2; day 1,8</other_name>
    <other_name>Trastuzumab; 6 mg/kg (loading dose 8 mg/kg); day 1</other_name>
    <other_name>Carboplatin; AUC=6; day 1</other_name>
    <other_name>Pertuzumab; 420 mg (loading dose 840 mg); day 1</other_name>
    <other_name>Cycle repeated every 21 days</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FEC-T+Pertuzumab</intervention_name>
    <arm_group_label>FEC-T +Pertuzumab</arm_group_label>
    <other_name>Fluorouracil; 500 mg/m2; day 1</other_name>
    <other_name>Epirubicine; 90 mg/m2; day 1</other_name>
    <other_name>Cyclophosphamide 500 mg/m2; day 1</other_name>
    <other_name>Trastuzumab; 6 mg/kg (loading dose 8 mg/kg)</other_name>
    <other_name>Pertuzumab; 420 mg (loading dose 840 mg); day 1</other_name>
    <other_name>Cycle is repeated every 21 days</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed infiltrating breast cancer

          -  Stage II or stage III disease. Nodal status must be examined by ultrasound, fine
             needle aspiration, sentinel node biopsy, or FDG-PET scan.

          -  Overexpression and/or amplification of HER2 in an invasive component of the core
             biopsy, according to one of the following definitions:

             •&gt;30% of invasive tumor cells showing strong complete circumferential membrane
             staining (score 3+)

             •HER2 gene amplification defined as &gt;6 HER2 gene copies per nucleus by in situ
             hybridization.

          -  Age ≥18

          -  Eastern Cooperative Oncology Group performance status ≤1

          -  Adequate bone marrow function (ANC &gt;1.5 x 109/l, platelets &gt;100 x 109/l)

          -  Adequate hepatic function (ALAT, ASAT and bilirubin &lt;2.5 times upper limit of normal)

          -  Adequate renal function (creatinine clearance &gt;50 ml/min)

          -  LVEF ≥50% measured by echocardiography or MUGA

          -  Absence of any psychological, familial, sociological, or geographical condition
             potentially hampering compliance with the study protocol and follow-up schedule

          -  Absence of any medical condition that would place the patient at unusual risk.

          -  Signed written informed consent

        Exclusion Criteria:

          -  previous radiation therapy or chemotherapy

          -  other malignancy except carcinoma in situ, unless the other malignancy was treated ≥5
             years ago with curative intent without the use of chemotherapy or radiation therapy.

          -  current pregnancy or breastfeeding. Women of childbearing potential must use adequate
             contraceptive protection

          -  evidence of distant metastases. Evaluation of the presence of distant metastases may
             include chest X-ray, liver ultrasound, isotope bone-scan, CT-scan of chest and
             abdomen and/or FDG-PET scan, according to local procedures.

          -  evidence of bilateral infiltrating breast cancer. Evaluation of the presence of
             bilateral infiltrating breast cancer may include mammography, breast ultrasound
             and/or MRI breast.

          -  concurrent anti-cancer treatment or another investigational drug.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gabe S Sonke, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Antoni van Leeuwenhoek, Amsterdam</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mette S van Ramshorst, MD</last_name>
    <phone>+3120512</phone>
    <phone_ext>6169</phone_ext>
    <email>m.v.ramshorst@nki.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gabe S Sonke, MD</last_name>
    <phone>+3120512</phone>
    <phone_ext>2951</phone_ext>
    <email>g.sonke@nki.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>MCA</name>
      <address>
        <city>Alkmaar</city>
        <zip>1815 JD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>S Vrijaldenhoven, MD</last_name>
    </contact>
    <investigator>
      <last_name>S Vrijaldenhoven, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ZGT</name>
      <address>
        <city>Almelo</city>
        <zip>7609 PP</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>I M Oving, MD</last_name>
      <email>i.oving@zgt.nl</email>
    </contact>
    <investigator>
      <last_name>I M Oving, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Antoni van Leeuwenhoek</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabe S Sonke, MD</last_name>
      <phone>+3120512</phone>
      <phone_ext>2951</phone_ext>
      <email>g.sonke@nki.nl</email>
    </contact>
    <contact_backup>
      <last_name>Mette S van Ramshorst, M</last_name>
      <phone>+3120512</phone>
      <phone_ext>6196</phone_ext>
      <email>m.v.ramshorst@nki.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Gabe S Sonke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>OLVG</name>
      <address>
        <city>Amsterdam</city>
        <zip>1090 HM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>J M Meerum Terwogt, MD</last_name>
    </contact>
    <investigator>
      <last_name>J M Meerum Terwogt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZVU</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rode Kruis Ziekenhuis</name>
      <address>
        <city>Beverwijk</city>
        <zip>1940 EB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>A N Goosens, MD</last_name>
      <email>agoosens@rkz.nl</email>
    </contact>
    <investigator>
      <last_name>A N Goosens, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Amphia ziekenhuis</name>
      <address>
        <city>Breda</city>
        <zip>4819 EV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>J B Heijns, MD</last_name>
      <email>JHeijns@amphia.nl</email>
    </contact>
    <investigator>
      <last_name>J B Heijns, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Reinier de Graaf Groep</name>
      <address>
        <city>Delft</city>
        <zip>2625 AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>V O Dezentje, MD</last_name>
    </contact>
    <investigator>
      <last_name>V O Dezentje, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jeroen Bosch Hospital</name>
      <address>
        <city>Den Bosch</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>T. Smilde, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>T. Smilde, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bronovo Ziekenhuis</name>
      <address>
        <city>den Haag</city>
        <zip>2597 AX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Haga</name>
      <address>
        <city>Den Haag</city>
        <zip>2545 CH</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>J E Portielje, MD</last_name>
      <email>j.portielje@hagaziekenhuis.nl</email>
    </contact>
    <investigator>
      <last_name>J E Portielje, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Deventer ziekenhuis</name>
      <address>
        <city>Deventer</city>
        <zip>7416 SE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>A L Imholz, MD</last_name>
      <email>imholza@dz.nl</email>
    </contact>
    <investigator>
      <last_name>A L Imholz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis Gelderse Vallei</name>
      <address>
        <city>Ede</city>
        <zip>6716 RP</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>A W Haringhuizen, MD</last_name>
      <email>haringhuizena@zgv.nl</email>
    </contact>
    <investigator>
      <last_name>A W Haringhuizen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maxima Medisch Centrum</name>
      <address>
        <city>Eindhoven</city>
        <zip>5631 BM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>L W Tick, MD</last_name>
    </contact>
    <investigator>
      <last_name>L W Tick, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Catharina Ziekenhuis</name>
      <address>
        <city>Eindhoven</city>
        <zip>5602 ZA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>St Anna Geldrop</name>
      <address>
        <city>Geldrop</city>
        <zip>5664 EH</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>A Smals, MD</last_name>
      <email>a.smals@st-anna.nl</email>
    </contact>
    <investigator>
      <last_name>A Smals, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Orbis Medisch Centrum</name>
      <address>
        <city>Geleen</city>
        <zip>6162 BG</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Groene Hart</name>
      <address>
        <city>Gouda</city>
        <zip>2803 HH</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>B C Tanis, MD</last_name>
      <email>bea.tanis@ghz.nl</email>
    </contact>
    <investigator>
      <last_name>B C Tanis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kennemer Gasthuis</name>
      <address>
        <city>Haarlem</city>
        <zip>2035 RC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Atrium Medisch Centrum Parkstad</name>
      <address>
        <city>Heerlen</city>
        <zip>6401 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>F van de Berkmortel, MD</last_name>
    </contact>
    <investigator>
      <last_name>F van de Berkmortel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spaarne ziekenhuis</name>
      <address>
        <city>Hoofddorp</city>
        <zip>2134 TM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>B de Valk, MD</last_name>
      <email>bdevalk@spaarneziekenhuis.nl</email>
    </contact>
    <investigator>
      <last_name>B de Valk, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Westfries Gasthuis</name>
      <address>
        <city>Hoorn</city>
        <zip>1624 NP</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>S M van den Heiligenberg, MD</last_name>
      <email>s.m.vandenheiligenberg@westfriesgasthuis.nl</email>
    </contact>
    <investigator>
      <last_name>S M van den Heiligenberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MCL</name>
      <address>
        <city>Leeuwarden</city>
        <zip>8934 AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>H de Graaf, MD</last_name>
      <email>graafhi@znb.nl</email>
    </contact>
    <investigator>
      <last_name>H de Graaf, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>LUMC</name>
      <address>
        <city>Leiden</city>
        <zip>2300 RC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Diaconessenhuis Meppel</name>
      <address>
        <city>Meppel</city>
        <zip>7943 KA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Canisius-Wilhelmina Hospital</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>C.M.P.W. Mandigers, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>C.M.P.W. Mandigers, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Waterlandziekenhuis</name>
      <address>
        <city>Purmerend</city>
        <zip>1441 RN</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Brakenhoff, MD</last_name>
      <email>brakenhoff@wlz.nl</email>
    </contact>
    <investigator>
      <last_name>Brakenhoff, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vlietland Ziekenhuis</name>
      <address>
        <city>Schiedam</city>
        <zip>3100 AE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Q C van Rossum-Schornagel, MD</last_name>
    </contact>
    <investigator>
      <last_name>Q C van Rossum-Schornagel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Elisabeth</name>
      <address>
        <city>Tilburg</city>
        <zip>5022 GC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>J M van Riel, MD</last_name>
      <email>jmgriel@elisabeth.nl</email>
    </contact>
    <investigator>
      <last_name>J M van Riel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Diaconessenhuis Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3582 KE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>D ten Bokkel Huinink, MD</last_name>
      <email>dtbokkel@diakhuis.nl</email>
    </contact>
    <investigator>
      <last_name>D ten Bokkel Huinink, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>VieCuri Medisch Centrum voor Noord-Limburg</name>
      <address>
        <city>Venlo</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Zaans Medisch Centrum</name>
      <address>
        <city>Zaandam</city>
        <zip>1502 DV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>S Bakker, MD</last_name>
      <email>bakker.sd@zaansmc.nl</email>
    </contact>
    <investigator>
      <last_name>S Bakker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Isala Klinieken</name>
      <address>
        <city>Zwolle</city>
        <zip>8025 AB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>A H. Honkoop, MD</last_name>
      <email>a.h.honkoop@isala.nl</email>
    </contact>
    <investigator>
      <last_name>A H Honkoop, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 22, 2014</lastchanged_date>
  <firstreceived_date>November 18, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>neoadjuvant</keyword>
  <keyword>breast cancer</keyword>
  <keyword>HER2 positive</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
